Trials / Completed
CompletedNCT02347917
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
A Phase I/II Clinical Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Sumitomo Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, phase 1/2 study of BBI608 in combination with pemetrexed and cisplatin chemotherapy as a 1st line treatment for Malignant Pleural Mesothelioma (MPM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BBI608 | 480 mg orally twice daily (960 mg total daily dose) |
| DRUG | Pemetrexed | 500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3). |
| DRUG | Cisplatin | 75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3). |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2018-05-31
- Completion
- 2018-05-31
- First posted
- 2015-01-28
- Last updated
- 2022-04-12
- Results posted
- 2021-10-01
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02347917. Inclusion in this directory is not an endorsement.